Struggling With Hair Loss? This First-Ever Prescription Gummy May Help
It's the first prescription hair regrowth gummy to hit the market, and it offers women a more convenient way to stay consistent with treatment, something Hers' chief medical officer and OB-GYN, Dr. Jessica Shepherd, says is often overlooked in traditional regimens.
"The gummy is a once-daily dose that's designed to help women stick to their prescribed hair regimens as deemed clinically necessary by their provider to address their individual needs," she says.
Hers
Shepherd told CNET that everything about the product, from the packaging to the vegan formula to the taste (green apple flavor) and texture, was crafted with women's preferences in mind. The goal is a treatment that feels more like a self-care ritual than a chore.
Why a gummy?
Unlike traditional pills or topicals, the Biotin plus Minoxidil Gummy was formulated with adherence in mind. The proprietary compounded formula allows providers to personalize each prescription to individual needs, including adjusting the dosage to minimize side effects or combining multiple ingredients to tackle various concerns simultaneously.
"By leveraging the power of personalization, we're making it possible for women to access treatment designed to address their individual needs for their unique body, lifestyle and goals. This is the benefit of compounding," says Shepherd.
How much does it cost, and where can I get it?
The Biotin plus Minoxidil Gummy is available through Hers after a virtual consultation with one of its licensed providers. Each prescription is customized based on your unique hair loss patterns and goals. Hers strives to offer patients affordable treatments without insurance (no insurance is accepted), and the gummies start at $35 per month.
To learn more or schedule a consultation, visit forhers.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Gastrointestinal cancers rising dramatically in people under 50
Gastrointestinal cancers, which include colorectal, stomach and pancreatic cancer, are rising dramatically in younger adults, though doctors aren't fully sure why. Even some of the possible causes require more research, they say. According to a review published Thursday in JAMA, gastrointestinal cancers have become the fastest-growing type of cancers diagnosed in adults younger than 50 in the U.S.. The review, one of the most comprehensive looks at gastrointestinal cancer trends, summarized the findings of major international and U.S. cancer databases, plus 115 papers on gastrointestinal cancers published from January 2014 to March 2025. The authors underscore the need for people to follow the screening guidelines for colorectal cancer, which suggest that people with an average risk start screening — usually a colonoscopy or stool test — at age 45. Since doctors don't routinely screen for pancreatic, stomach and esophageal cancers in the U.S., the authors also call for new ways to screen more people for these cancers. 'This really points to the importance of trying to improve screening and early detection,' said Dr. Kimmie Ng, the review's co-author and director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute. According to the review, colorectal cancer is by far the most common early-onset gastrointestinal cancer, with nearly 185,000 cases reported worldwide in 2022 and nearly 21,000 cases reported that same year in the U.S. Diagnoses in the U.S. have risen 2% annually in people younger than 50 since 2011, according to the American Cancer Society. 'It never used to happen in this age group, and now a very significant rise in 20, 30 and 40-year-olds are getting colon cancer,' said Dr. John Marshall, chief medical consultant at the nonprofit Colorectal Cancer Alliance, who was not involved in the research. In one of the most high-profile examples, actor Chadwick Boseman was diagnosed with colon cancer in 2016 and passed away of the disease four years later at age 43. Early-onset cases of pancreatic, stomach and esophageal cancers are also rising, according to the new study. Previous research has shown a disproportionate share of those gastrointestinal cancer diagnoses were among Black and Hispanic people. Pancreatic cancer is among the deadliest forms of cancer, with just 13% of patients surviving five years after their diagnosis. Because colorectal cancer is the most common, doctors said they have a better grasp of what might be contributing to these early-onset cases compared to others. 'If we can understand what's going on in colorectal [cancer], I think it would really provide a lot of guidance to help us understand the other GI tract cancers,' said Dr. Scott Kopetz, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center. Kopetz said there are likely multiple factors driving the increase in early-onset cases. 'The leading theory is that there is no single leading theory,' he said. Ng's new review in JAMA suggests that most gastrointestinal cancers in people under 50 are associated with lifestyle factors such as obesity, lack of exercise, poor diet, cigarette smoking or alcohol consumption. One study included in the review found that women who consumed more sugar-sweetened beverages during adolescence had a higher risk of developing early onset colorectal cancer. 'It's really what people were doing or exposed to when they were infants, children, adolescents that is probably contributing to their risk of developing cancer as a young adult,' Ng said. Health and Human Services Secretary Robert F. Kennedy Jr. has been vocal about the association between sugary beverages and health issues, including cancer. On Wednesday, President Donald Trump said Coca-Cola will start being made with cane sugar rather than corn syrup in the U.S., but the company did not commit to the change when asked about it by NBC News. Marshall said he suspects the rise in early-onset colorectal cancer could have something to do with changes in people's gut microbiomes — the bacteria that live in our gastrointestinal tracts. Diet, antibiotic use, microplastics and exposure to environmental chemicals likely all influence a person's gut bacteria, but scientists still don't have a clear understanding of what a healthy microbiome looks like nor how it affects our health. That is a booming area of research. Ng's review also found that 15% to 30% of people with early-onset gastrointestinal cancer carry hereditary genetic mutations that may have predisposed them to getting cancer at a young age. Because of that, she said, 'we do recommend that all young patients diagnosed under the age of 50 undergo testing for hereditary conditions.' Overall survival rates for gastrointestinal cancers have gotten better over time, due to improvements in treatment and screening. But Ng's review found that younger patients often have worse outcomes, despite typically receiving more treatments, including more surgery, radiation and aggressive combinations of chemotherapy, she said. One reason could be that primary care doctors may overlook symptoms such as abdominal pain, constipation, heartburn or reflux in younger patients, thereby delaying their diagnoses. 'My personal feeling is that it's because we're finding them at a more advanced stage, because people don't really think of colon or other GI cancers when they see a young person with these non-specific complaints,' said Dr. Howard Hochster, director of gastrointestinal oncology at Rutgers Cancer Institute and RWJBarnabas Health in New Jersey. But Ng said that even after controlling for the stage at which patients are diagnosed, young people still seem to have worse survival rates. 'This makes us wonder as researchers whether that means that the cancers that develop in younger people may be biologically different and more aggressive, or maybe less responsive to treatment,' she said. This article was originally published on Solve the daily Crossword
Yahoo
4 minutes ago
- Yahoo
Peach State Health Plan's $27.7M Investment Shows Strong Commitment to Member Wellness
ATLANTA, July 17, 2025 /PRNewswire/ -- Peach State Health Plan (PSHP) has invested $27.7 million in additional Medicaid benefits from 2022 through 2024. Known as Value-Added Benefits (VABs), this includes services and activities designed to encourage healthy behaviors, strengthen care connections, and improve overall access to support. They are meaningful, real-life resources that help the health plan's most vulnerable members stay covered, well, and supported. Some restrictions and limitations may apply. Over the past three years, 20% of PSHP's total VABs spending, or $5.4 million, was dedicated to vision care. Additional investments included $5.0 million for My Health Pays (Wellness Works), $4.3 million for Over-the-Counter (OTC) items, and $3.4 million for dental care. "Our mission is rooted in supporting the communities we serve," said Clyde White, President and CEO of Peach State Health Plan. "This investment is another way we are delivering on that promise, providing our members with resources that go beyond basic healthcare, so they can live healthier lives." This year's VABs portfolio reflects on PSHP's commitment to supporting members' day-to-day needs and placing a stronger focus on removing barriers to care especially those tied to social drivers of health (SDOH). From job training and mental health tools to emergency childcare, every benefit is a touchpoint that shows members that they matter, and that Medicaid means more. Here is some of what's included in PSHP's 2025–2026 benefit cycle: Up to six months of emergency childcare support provided through Quality Care for Children for eligible members facing urgent needs such as interviews, medical visits, or loss of care. New 24/7 mental health support through Pyx Health gives members free, anytime access to emotional check-ins, encouragement, and real human connection. Up to $240 each year to shop for everyday health essentials like cold medicine, toothpaste, and other care items at no cost through the Over-the-Counter (OTC) Benefit, making it easier to stay healthy while and stretch household budgets. School-Break Grocery Allowance: Provides eligible Medicaid families with a prepaid card to help cover the cost of healthy groceries when school meals aren't available. Free annual eye exam and $100 toward glasses, contacts or broken frames through our Vision Benefit. Work-Ready Scholarships which equips eligible members with career-boosting job training and certifications through Goodwill Industries, helping them gain in-demand skills and enter the workforce with confidence. "Peach State Health Plan is committed to going beyond traditional healthcare by addressing the everyday needs of our members," said Tara Freeney, Senior Director of Commercial Operations. "The investment in Value-Added Benefits reflects a dedication to improving quality of life across Georgia to meet members where they are and support healthier futures." PSHP's Value-Added Benefits are reviewed and updated every year for launch on July 1. To see a full list of available benefits, visit About Peach State Health Plan Peach State Health Plan is a care management organization that serves the needs of Georgians through a range of health insurance solutions. Peach State Health Plan serves the Medicaid and PeachCare for Kids® population in partnership with Georgia Families. The organization also focuses on under-insured and uninsured individuals through its federal insurance marketplace plan, Ambetter, and its Medicare Advantage Special Needs Plan. Peach State Health Plan is a Centene company, a leading healthcare enterprise committed to helping people live healthier lives. For more information visit View original content to download multimedia: SOURCE Peach State Health Plan Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors
Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year. The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. Second-quarter sales increased 7.4% on a reported basis, 6.9% on an organic basis, or 7.5% when excluding COVID-19 testing-related U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27. 'Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,' said Robert B. Ford, chairman and chief executive officer, Abbott. 'We see this momentum carrying into 2026.' Medical Devices sales increased 13.4% on a reported basis and 12.2% on an organic basis to $5.37 billion. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. Several products contributed to the performance, including FreeStyle Libre, Navitor, TriClip, and AVEIR. In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4% on a reported basis and 19.6% organically. Worldwide Nutrition sales increased 2.9% (+3.4% on an organic basis) to $2.21 billion. View more earnings on ABT Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1% (+6.6% on an organic basis), led by strong growth of Ensure and Glucerna. Global Diagnostics sales decreased 1% (-1.4% on an organic basis) and increased 0.8% when excluding COVID-19 testing-related sales. The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million a year ago. Established Pharmaceuticals sales increased 6.9% (+7.7% on an organic basis) to $1.38 billion. Abbott's reported operating margin of 18.4%, with an adjusted operating margin of 22.9%, which reflects a 100 basis point increase. Guidance Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16. The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%. Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share. During the earnings conference call, an Abbott executive addressed the impact of tariffs, reporting that the estimated headwind has been revised down to $200 million for the year, lower than previous estimates. Price Action: ABT stock is trading lower by 8.00% to $121.21 at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
